Telmisartan Actavis | European Medicines Agency (EMA)

[ad_1]

Overview

This is a summary of the European public assessment report (EPAR) for Telmisartan Actavis. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Telmisartan Actavis.

Telmisartan Actavis is a medicine that contains the active substance telmisartan. It is available as tablets (20 mg; 40 and 80 mg).

Telmisartan Actavis is a ‘generic medicine’. This means that Telmisartan Actavis is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Micardis.

Telmisartan Actavis is used to treat essential hypertension (high blood pressure) in adults. ‘Essential’ means that the hypertension has no obvious cause.

Telmisartan Actavis is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes. It is used in patients who have had problems due to blood clots in the past (such as heart disease, a stroke or artery disease) or who have type 2 diabetes that has damaged an organ (such as the eyes, heart or kidneys).

The medicine can only be obtained with a prescription.

For the treatment of essential hypertension, the usual recommended dose of Telmisartan Actavis is 40 mg once a day, but some patients may benefit from using 20mg once a day. If the target blood pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.

For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day. The doctor should monitor the patient’s blood pressure closely when starting Telmisartan Actavis, and may decide to adjust the patient’s blood-pressure-lowering medication. Patients with severely reduced kidney function should receive a lower starting dose of 20 mg once a day. Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day.

The active substance in Telmisartan Actavis, telmisartan, is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen. This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack or stroke. It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.

Because Telmisartan Actavis is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

Because Telmisartan Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The CHMP concluded that, in accordance with EU requirements, Telmisartan Actavis has been shown to have comparable quality and to be bioequivalent to Micardis. Therefore, the CHMP’s view was that, as for Micardis, the benefit outweighs the identified risk. The Committee recommended that Telmisartan Actavis be given marketing authorisation.

The European Commission granted a marketing authorisation valid throughout the European Union for Telmisartan Actavis on 30 September 2010.

For more information about treatment with Telmisartan Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

English (EN)
(70.58 KB – PDF)

First published: 20/10/2010Last updated: 28/07/2015

View

Product information

English (EN)
(699.42 KB – PDF)

First published: 20/10/2010Last updated: 28/01/2025

View

Latest procedure affecting product information:
VR/0000245919

28/01/2025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(28.13 KB – PDF)

First published: 20/10/2010Last updated: 14/11/2011

View

Product details

Name of medicine: Telmisartan Actavis
Active substance: Telmisartan
International non-proprietary name (INN) or common name: telmisartan
Therapeutic area (MeSH): Hypertension
Anatomical therapeutic chemical (ATC) code: C09CA07

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Hypertension

Treatment of essential hypertension in adults.

Cardiovascular prevention

Reduction of cardiovascular morbidity in patients with:

manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;
type 2 diabetes mellitus with documented target organ damage.

[ad_2]

Source link

Subscribe now

To access premium content

Ubisoft To Develop Blockchain Games, Enjin’s $100 Million Fund

All About Play to Earn With Crypto Games (P2E)

Blockchain Gaming Industry & 5 Crypto Games to Watch

Ethereum Still Leads The Way in Blockchain Gaming

What is Binamon? Ready For Launch On August 28

Binapet Review: Breeding BSC Play-to-Earn Game

The Galaxy of Lemuria Review – Play To Earn MMORPG

BLAST Premier 2022 – Betting Tips and Schedule

Zendodo Party Review: Where NFTs Meets DeFi on WAX

BLAST Premier 2022 – Betting Tips and Schedule

Is Overwatch League Getting Outsourced A Good Thing?

Genesis Worlds Interview With CEO Jason Cassidy

Dreamverse NFT Festival: Interview With Twobadour

Inside Axie Infinity With Jihoz – Growth Lead